Camrelizumab (also known as SHR-1210) is a high-affinity, humanized IgG4-κ monoclonal antibody. It exhibits a strong binding affinity to PD-1, with a Kd of 3 nM, and effectively prevents the engagement of PD-1 with its ligand PD-L1, achieving an IC50 of 0.70 nM. Functioning as an anti-PD-1/PD-L1 therapeutic, Camrelizumab is valuable in oncology research and treatment, with applications in various malignancies such as non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), Hodgkin's lymphoma, and advanced hepatocellular carcinoma (HCC), among others[1][2].
Camrelizumab induced T-cell proliferation at an EC50 of 0.11 nM in peripheral blood mononuclear cells treated with tuberculin, and it induced the production of IFN-gamma at an EC50 of 0.38 nM in a similar assay measuring IFN-gamma secretion[2].
Camrelizumab (dosed at 3 mg/kg) and apatinib (dosed at 200 mg/kg and 100 mg/kg) exhibited tumor growth inhibition rates of 63.1% and 87.3%, respectively, in human PD-1 transgenic mice. Camrelizumab blocked the binding of PD-1 to its ligand PD-L1, which relieved the immune suppression in the tumor microenvironment, enhanced the activity of T cells, and thus improved the immune response against tumors[1].
References:
[1] Kuimin Mei, et al. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial. J Immunother Cancer. 2021 Mar;9(3):e002191.
[2]Jason D Lickliter, et al. A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia. Drug Des Devel Ther. 2020 Mar 18:14:1177-1189.
卡瑞利珠单抗（Camrelizumab, 也称为SHR-1210）是一种高亲和力、人源化IgG4-κ单克隆抗体。它对PD-1具有强烈的结合亲和力，Kd值为3 nM，并且有效阻止PD-1与其配体PD-L1的结合，IC50达到0.70 nM。作为一种抗PD-1/PD-L1治疗剂，卡瑞利珠单抗在肿瘤学研究和治疗中具有重要价值，适用于多种恶性肿瘤，如非小细胞肺癌（NSCLC）、食管鳞状细胞癌（ESCC）、霍奇金淋巴瘤和晚期肝细胞癌（HCC）等[1][2]。
卡瑞利珠单抗在结核菌素处理的外周血单核细胞中诱导T细胞增殖的EC50为0.11 nM，以及在测量IFN-gamma分泌的类似测定中，以0.38 nM的EC50诱导IFN-gamma的产生[2]。
卡瑞利珠单抗（剂量为3 mg/kg）与阿帕替尼（剂量为200 mg/kg和100 mg/kg）在人PD-1转基因小鼠中的肿瘤生长抑制率分别为63.1%和87.3%，卡瑞利珠单抗通过阻断PD-1与其配体PD-L1的结合，解除肿瘤微环境中的免疫抑制，增强T细胞的活性，从而提高对肿瘤的免疫反应[1]。